Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Infectious diseases

An Unlikely Source of Inspiration

The Bacille Calmette-Guérin (BCG) tuberculosis (TB) vaccine is one of the most widely used vaccines globally, but it doesn’t stop there – even at 101 years old, the vaccine may still be a source of inspiration for future vaccine design. It has previously been suggested that BCG’s effects may extend beyond TB to protect infants against other bacterial and viral infections, but the mechanisms remain unclear. Might the answer lie in its origins?

“Unlike many newer vaccines, BCG is made from a live, weakened germ, and may offer unique mechanisms of protection,” said Ofer Levy, director of the Precision Vaccines Program at Boston Children’s Hospital (1). “It’s critical that we learn from BCG so we can better protect newborns, whose immune systems are distinct from those of adults.”

To investigate this, researchers from the Boston Children’s Hospital and the Expanded Program on Immunization Consortium used mass spectrometry-based metabolomics of blood plasma to characterize BCG-induced responses in infants (2). They found that vaccinated infants had distinct metabolic and lipid profiles in their blood compared with unvaccinated infants and that the vaccine’s effects on lysophosphatidylcholines (LPCs) were associated with cytokine responses – suggesting that LPCs may contribute to BCG immunogenicity.

“Old vaccines like BCG seem to activate the immune system in a very different way in early life, providing broad protection against a range of bacterial and viral infections,” said Levy (1). The study is one of the first to characterize BCG-induced changes to the human newborn plasma metabolome; previous studies in neonates have used umbilical cord blood for metabolomic profiling.

“We now have some lipid and metabolic biomarkers of vaccine protection that we can test and manipulate in mouse models,” said lead author Joann Diray Arce (1). The next step of the project is to perform that further testing – but there is still much work to be done to fully understand the vaccine’s broad protective effects and apply this to developing better vaccines for infants.

Hero and Teaser Credit: Image sourced from Pixabay.com

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Nancy Fliesler (2022). Available at: https://on.bchil.org/3R2oMOz.
  2. J Diray-Arce et al., Cell Rep, 39, 110772 (2022). PMID: 35508141.
About the Author
Olivia Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register